NASDAQ:CVKD Cadrenal Therapeutics (CVKD) Stock Price, News & Analysis $7.29 +0.04 (+0.55%) (As of 10:50 AM ET) Add Compare Share Share Today's Range$7.08▼$7.6950-Day Range$0.40▼$7.2552-Week Range$5.40▼$32.55Volume26,984 shsAverage Volume19,346 shsMarket Capitalization$116.70 millionP/E RatioN/ADividend YieldN/APrice Target$3.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get Cadrenal Therapeutics alerts: Email Address Cadrenal Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside51.7% Downside$3.50 Price TargetShort InterestHealthy0.57% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.36) to ($0.34) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.46 out of 5 starsMedical Sector887th out of 924 stocksPharmaceutical Preparations Industry413th out of 426 stocks 1.5 Analyst's Opinion Consensus RatingCadrenal Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCadrenal Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Cadrenal Therapeutics' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.57% of the float of Cadrenal Therapeutics has been sold short.Short Interest Ratio / Days to CoverCadrenal Therapeutics has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Cadrenal Therapeutics has recently increased by 67.24%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldCadrenal Therapeutics does not currently pay a dividend.Dividend GrowthCadrenal Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CVKD. Previous Next 1.5 News and Social Media Coverage News SentimentCadrenal Therapeutics has a news sentiment score of -0.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.44 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Cadrenal Therapeutics this week, compared to 0 articles on an average week.Search Interest1 people have searched for CVKD on MarketBeat in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cadrenal Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders48.62% of the stock of Cadrenal Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 7.92% of the stock of Cadrenal Therapeutics is held by institutions.Read more about Cadrenal Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Cadrenal Therapeutics are expected to grow in the coming year, from ($0.36) to ($0.34) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cadrenal Therapeutics is -23.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cadrenal Therapeutics is -23.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCadrenal Therapeutics has a P/B Ratio of 12.29. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Cadrenal Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaThis Crypto Is Set to Explode in AugustWith thousands of cryptocurrencies out there, it's crucial to focus on the ONE that has the potential to make HUGE gains. Industry Giants are Investing Heavily in Blockchain Technology and THIS COIN is at the Heart of Their Strategy. It's a groundbreaking opportunity that could be poised for extraordinary gains. Go here to get full details on this crypto now. About Cadrenal Therapeutics Stock (NASDAQ:CVKD)Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc. was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.Read More CVKD Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CVKD Stock News HeadlinesAugust 22 at 9:00 AM | prnewswire.comCadrenal Therapeutics Announces Upcoming Type-B FDA Meeting in September to Discuss Tecarfarin Trial in LVAD PatientsAugust 20 at 9:00 AM | prnewswire.comPublished Findings Highlight Tecarfarin's Potential and Reinforce Need for Better Anticoagulation Therapy in LVAD PatientsAugust 22, 2024 | Crypto 101 Media (Ad)This Crypto Is Set to Explode in AugustWith the 2024 Bitcoin Halving, there's a potential HUGE bull run for altcoins. While everyone's chasing the latest DeFi craze or the next hot meme coin, the savviest investors are quietly positioning themselves for a different kind of explosion. This year's Bitcoin halving bull run is about to unleash a tidal wave in a completely undervalued sector of the crypto market.August 14, 2024 | prnewswire.comCadrenal Therapeutics to Present at Upcoming Investor ConferencesAugust 13, 2024 | americanbankingnews.comHC Wainwright Comments on Cadrenal Therapeutics, Inc.'s Q3 2024 Earnings (NASDAQ:CVKD)August 7, 2024 | msn.comCVKD: Cadrenal Therapeutics and Abbott Collaborate on Novel Anticoagulant for LVAD PatientsAugust 7, 2024 | prnewswire.comCadrenal Therapeutics Provides Second Quarter 2024 Corporate UpdateAugust 6, 2024 | prnewswire.comCadrenal Therapeutics and Abbott Initiate Collaborative Effort to Advance Novel Anticoagulant Tecarfarin for Patients with LVADsAugust 22, 2024 | Crypto 101 Media (Ad)This Crypto Is Set to Explode in AugustWith the 2024 Bitcoin Halving, there's a potential HUGE bull run for altcoins. While everyone's chasing the latest DeFi craze or the next hot meme coin, the savviest investors are quietly positioning themselves for a different kind of explosion. This year's Bitcoin halving bull run is about to unleash a tidal wave in a completely undervalued sector of the crypto market.July 17, 2024 | prnewswire.comCadrenal Therapeutics to Present at the Emerging Growth Conference on July 18, 2024June 11, 2024 | prnewswire.comCadrenal Therapeutics to Present at the Emerging Growth Conference on June 12, 2024June 3, 2024 | prnewswire.comCadrenal Therapeutics Highlights Presentation of New Trial Data at ISHLT Conference Demonstrating the Importance of Anticoagulation Quality in LVAD PatientsMay 23, 2024 | prnewswire.comCadrenal Therapeutics to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024May 10, 2024 | markets.businessinsider.comBuy Rating Affirmed for Cadrenal Therapeutics on Strong Clinical and Financial ProspectsMay 9, 2024 | prnewswire.comCadrenal Therapeutics Provides First Quarter 2024 Corporate UpdateApril 20, 2024 | finance.yahoo.comFavourable Signals For Cadrenal Therapeutics: Numerous Insiders Acquired StockApril 11, 2024 | finance.yahoo.comCadrenal Therapeutics to Participate in Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference on April 18, 2024April 11, 2024 | prnewswire.comCadrenal Therapeutics to Participate in Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference on April 18, 2024See More Headlines Receive CVKD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cadrenal Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today8/22/2024Next Earnings (Estimated)8/22/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CVKD CUSIPN/A CIK1937993 Webwww.cadrenal.com Phone904-300-0701FaxN/AEmployees4Year FoundedN/APrice Target and Rating Average Stock Price Target$3.50 High Stock Price Target$4.00 Low Stock Price Target$3.00 Potential Upside/Downside-52.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.31) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-8,360,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-75.11% Return on Assets-68.16% Debt Debt-to-Equity RatioN/A Current Ratio8.21 Quick Ratio8.21 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.59 per share Price / Book12.36Miscellaneous Outstanding Shares16,008,000Free Float8,225,000Market Cap$116.70 million OptionableNot Optionable Beta1.71 20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free Report Key ExecutivesMr. Quang X. Pham (Age 59)Chairman & CEO Comp: $967kMr. Matthew K. Szot CPA (Age 50)CPA, Chief Financial Officer Comp: $594.89kDr. Douglas W. Losordo FACC (Age 66)FAHA, M.D., Chief Medical Officer Comp: $528.69kMr. Jeffrey ColeChief Operating OfficerKey CompetitorsCognition TherapeuticsNASDAQ:CGTXRenovoRxNASDAQ:RNXTMiNK TherapeuticsNASDAQ:INKTZIVO BioscienceNASDAQ:ZIVOOrgenesisNASDAQ:ORGSView All CompetitorsInsiders & InstitutionsRenaissance Technologies LLCSold 88,647 shares on 8/9/2024Ownership: 0.372%John Raymond MurphyBought 17,331 shares on 10/4/2023Total: $12,131.70 ($0.70/share)Quang X PhamBought 70,000 shares on 9/1/2023Total: $63,700.00 ($0.91/share)View All Insider TransactionsView All Institutional Transactions CVKD Stock Analysis - Frequently Asked Questions How have CVKD shares performed this year? Cadrenal Therapeutics' stock was trading at $0.7399 at the beginning of the year. Since then, CVKD shares have increased by 879.9% and is now trading at $7.25. View the best growth stocks for 2024 here. When did Cadrenal Therapeutics IPO? Cadrenal Therapeutics (CVKD) raised $7 million in an initial public offering (IPO) on Friday, January 20th 2023. The company issued 1,400,000 shares at a price of $5.00 per share. Who are Cadrenal Therapeutics' major shareholders? Cadrenal Therapeutics' top institutional shareholders include Renaissance Technologies LLC (0.37%). View institutional ownership trends. How do I buy shares of Cadrenal Therapeutics? Shares of CVKD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CVKD) was last updated on 8/22/2024 by MarketBeat.com Staff From Our PartnersWhat Is the $7,882 Stimulus Payment 2024?Biden’s government just announced a new government "stimulus program"... And it could hand you a payment fo...Angel Publishing | SponsoredAir Force quietly working with sub $10 stock on new techThere is a little-known energy technology stock that has made an incredible breakthrough… Which could becom...DTI | SponsoredTrump is sounding the alarmEurope is one of the latest to release a central bank digital currency and along with it, new cash rules. Chri...Preserve Gold | SponsoredUS developing “superweapon” to defeat China and Russia?Our new superweapon is a gift to every patriot. I predict the devastating new tech behind this weapon will cre...Paradigm Press | SponsoredGrab this ETF paying a huge 22% dividendImagine a world where you don't have to stress about inflation eroding your savings... Where your paycheck ...Investors Alley | SponsoredAmazon coin set to soar 25X – starting August 19thChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredAlex's "Next Magnificent Seven" StocksToday Alex Green is releasing his new breakdown of AI's "Next Magnificent Seven." So please make some time ...The Oxford Club | Sponsored625,000% GainThe recent crypto pullback has been brutal, causing widespread panic among investors. But for us, it’s just an...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cadrenal Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cadrenal Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
